<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00941746</url>
  </required_header>
  <id_info>
    <org_study_id>PG110-01</org_study_id>
    <secondary_id>2008-006219-19</secondary_id>
    <nct_id>NCT00941746</nct_id>
  </id_info>
  <brief_title>Safety and Tolerability of PG110 in Patients With Knee Osteoarthritis Pain</brief_title>
  <official_title>A Randomised, Double-blind, Placebo-controlled, Single Ascending Dose, Phase I Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of PG110 (Anti-NGF Monoclonal Antibody) in Patients With Pain Attributed to Osteoarthritis of the Knee</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety and tolerability of a single intravenous
      dose of PG110, a monoclonal antibody that inhibits the effects of the naturally occurring
      substance, nerve growth factor (NGF).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>August 2009</start_date>
  <completion_date type="Actual">January 2011</completion_date>
  <primary_completion_date type="Actual">January 2011</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The number and severity of adverse events</measure>
    <time_frame>Three months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Terminal elimination half-life</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Dose proportionality of the area under the serum concentration-time curve</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pain in the index knee</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Western Ontario and McMaster Universities questionnaire</measure>
    <time_frame>Three months</time_frame>
  </secondary_outcome>
  <number_of_arms>9</number_of_arms>
  <enrollment type="Actual">56</enrollment>
  <condition>Osteoarthritis, Knee</condition>
  <arm_group>
    <arm_group_label>Lowest dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Second dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Third dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fourth dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fifth dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Top dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion that matches PG110 in appearance</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Seventh Dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Eight Dose of PG110</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single, slow intravenous infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Lowest dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Second dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Third dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Fourth dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Fifth dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Top dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Seventh Dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>PG110</intervention_name>
    <description>Single, slow intravenous infusion</description>
    <arm_group_label>Eight Dose of PG110</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Single, slow intravenous infusion that matches PG110 in appearance</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Moderate to severe pain attributed to knee osteoarthritis

        Exclusion Criteria:

          -  Significant comorbidity

          -  Significant pain states other than osteoarthritis

          -  Concomitant medications that might affect assessments
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jerry Hall, MD</last_name>
    <role>Study Director</role>
    <affiliation>Abbott</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site Ref # / Investigator 51568</name>
      <address>
        <city>Utrecht</city>
        <zip>3584 CJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>May 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2009</study_first_submitted>
  <study_first_submitted_qc>July 17, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 20, 2009</study_first_posted>
  <last_update_submitted>June 3, 2011</last_update_submitted>
  <last_update_submitted_qc>June 3, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 7, 2011</last_update_posted>
  <responsible_party>
    <name_title>Jerry A Hall, Medical Director</name_title>
    <organization>Abbott</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

